Clinical Trial Update: Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating secukinumab for safety and efficacy in Juvenile Psoriatic Arthritis and Enthesitis-related Arthritis has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enthesitis-related Arthritis
• Juvenile Psoriatic Arthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2022-08-15